首页GLSHQ • OTCMKTS
Gelesis Holdings Inc
$0.00
12月18日, GMT-5 17:20:00 · USD · OTCMKTS · 免责声明
股票在美国上市的证券总部位于美国
昨日收盘价
$0.00
市值
70.00 USD
平均交易量
952.00
市盈率
-
股息率
-
主要交易所
OTCMKTS
市场资讯
财务信息
损益表
收入
净收入
(USD)2023年6月年同比变化
收入
110.70万
经营支出
1060.50万
净收入
-768.10万
净利润率
-693.86
每股收益
息税折旧摊销前利润
-793.00万
有效税率
总资产
负债总额
(USD)2023年6月年同比变化
现金及短期投资
790.90万
总资产
9587.50万
负债总额
1.14亿
权益总额
-1862.50万
发行在外的股份
7333.51万
市净率
-0.00
资产回报率
-25.68%
资本回报率
-55.33%
现金净变动
(USD)2023年6月年同比变化
净收入
-768.10万
来自运营的现金
61.70万
投资现金
-1.80万
融资现金
417.30万
现金净变动
480.60万
自由现金流
382.14万
简介
Gelesis is a biotechnology company located in Boston, Massachusetts that developed the weight loss device Gelesis100 for use in overweight and obesity. The company produces Gelesis100, which is a superabsorbent hydrogel capsule that expands in the stomach, creating a feeling of fullness, helping people reduce the amount of food they eat. The company was founded in 2006 to develop medical devices and treatments for obesity. Gelesis Holdings, Inc. together with its two affiliates, filed for voluntary Chapter 7 liquidation in the United States Bankruptcy Court for the District of Delaware on October 30, 2023. The debtor listed its assets among the 50 and the $100 million and liabilities of $44.34 million. The Debtor is represented by Kenneth Listwak of Troutman Pepper Hamilton Sanders LLP as counsel. Wikipedia
成立时间
2006
员工数量
93
搜索
清除搜索内容
关闭搜索框
Google 应用
主菜单